Do African-American men need separate prostate cancer screening guidelines?

Divya Shenoy, Satyaseelan Packianathan, Allen M Chen, Srinivasan Vijayakumar, Divya Shenoy, Satyaseelan Packianathan, Allen M Chen, Srinivasan Vijayakumar

Abstract

Background: In 2012, the United States Preventative Services Task Force issued new guidelines recommending that male U.S. residents, irrespective of race, no longer be screened for prostate cancer. In African American men, the incidence of prostate cancer is almost 60 % higher and the mortality rate is two to three times greater than in Caucasians. The purpose of this study is to reduce African American men's prostate cancer burden by demonstrating they need separate screening guidelines.

Methods: We performed a PubMed search using the keywords: African American, Prostate cancer, Outcomes, Molecular markers, Prostate-specific Antigen velocity, PSA density, and to derive data relevant to our hypothesis.

Results: In our literature review, we identified several aspects of prostate cancer that are different in Caucasian and African American men. These included prostate cancer incidence and outcome, the clinical course of the disease, serum PSA levels, genetic differences, and social barriers. It's also important to note that the USPSTF guidelines were based on two studies, one of which reported that only 4 % of its participants were African American. The other did not report demographic information, but used participants from seven European countries with small African American populations.

Conclusion: Given the above, we conclude that separate prostate cancer screening guidelines are greatly necessary to help save the lives of African Americans.

Keywords: African Americans; Prostate cancer; Screening guidelines.

References

    1. Siegel RL, Miller KD, Jemal A. Cancer Statistics 2015. CA Cancer J Clin. 2015;65(1):5–29. doi: 10.3322/caac.21254.
    1. SEER Cancer Statistics Review, 1975–2006. National Cancer Institute Web site. Published 2009. Accessed 01 June 2015.
    1. Odedina FT, Akinremi TO, Chinewundoh F, Roberts R, Yu D, Reams RR, et al. Prostate cancer disparities in Black men of African descent: a comparative literature review of prostate cancer burden among Black men in the United States, Caribbean, United Kingdom, and West Africa. Infect Cancer Agent. 2009;4(1):S2. doi: 10.1186/1750-9378-4-S1-S2.
    1. Behavioral Risk Factor Surveillance System Survey Data. Center for Disease Control and Prevention. Published 2009. Accessed 03 June 2015.
    1. Powell IJ, Heilbrun L, Littrup PL, Franklin A, Parzuchowski J, Gelfand D, et al. Outcome of African American men screened for prostate cancer: the Detroit Education and Early Detection Study. J Urol. 1997;158(1):146–9. doi: 10.1097/00005392-199707000-00045.
    1. Underwood W, De Monner S, Ubel P, Fagerlin A, Sanda MG, Wei JT. Racial/ethnic disparities in in the treatment of localized/regional prostate cancer. J Urol. 2004;171(4):1504–7. doi: 10.1097/01.ju.0000118907.64125.e0.
    1. Powell IJ, Bock CH, Ruterbush JJ, Sakr W. Evidence supports a faster growth rate and/or earlier transformation to clinically signifiant prostate cancer in black than in white American men, and influences racial progression and mortality disparity. J Urol. 2010;183(5):1792–6. doi: 10.1016/j.juro.2010.01.015.
    1. Henderson RJ, Eastham JA, Culkin DJ, Whatley T, Mata J, Venable D, et al. Prostate Specific Antigen (PSA) and PSA Density: Racial Differences in Men Without Prostate Cancer. J Natl Cancer Inst. 1997;89(2):134–8. doi: 10.1093/jnci/89.2.134.
    1. McIntosh H. Why Do African-American Men Suffer More Prostate Cancer? J Natl Cancer Inst. 1997;89(3):188–9. doi: 10.1093/jnci/89.3.188.
    1. Du XL, Fang S, Coker AL, Sanderson M, Aragaki C, Cormier JN, et al. Racial disparity and socioeconomic status in association with survival in older men with local/regional stage prostate carcinoma: findings from a large community-based cohort. Cancer. 2006;106(6):1276–85. doi: 10.1002/cncr.21732.
    1. Ward E, Jemal A, Cokkinides V, Singh GK, Carinez C, Ghafoor A, et al. Cancer disparities by race/ethnic and socioeconomic status. CA Cancer J Clin. 2004;54(2):78–93. doi: 10.3322/canjclin.54.2.78.
    1. Whittemore AS, Kolonel LN, Wu AH, John EM, Gallagher RP, Howe GR, et al. Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J Natl Cancer Inst. 1995;87(9):652–61. doi: 10.1093/jnci/87.9.652.
    1. Abdalla I, Ray P, Ray V, Vaida F, Vijaykumar S. Comparison of serum prostate-specific antigen levels and PSA density in African-American, white, and Hispanic men without prostate cancer. Urology. 1998;51(2):300–5. doi: 10.1016/S0090-4295(97)00617-1.
    1. Vijayakumar S, Winter K, Sause W, Gallagher MJ, Michalski J, Roach M, et al. Prostatespecific antigen levels are higher in African-American than in white patients in a multicenter registration study: results of a RTOG 94–12. Int J Radiat Oncol Biol Phys. 1998;40(1):17–25. doi: 10.1016/S0360-3016(97)00834-1.
    1. Preston DM, Levin LI, Jacobson DJ, Jacobson SJ, Rubertone M, Holmes E, et al. Prostate specific antigen levels in young white and black men 20–45 years old. Urology. 2000;56(5):812–5. doi: 10.1016/S0090-4295(00)00764-0.
    1. Final Recommendation Statement: Prostate Cancer: Screening. U.S. Preventive Services Task Forcewebsite. RecommendationStatementFinal/prostate-cancer-screening Published 2014. Accessed 04 June 2015.
    1. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 2012;366(11):981–90. doi: 10.1056/NEJMoa1113135.
    1. Andriole GL, Crawford ED, Grubb RL, 3rd, Buys S, Chia D, Church TR, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104(2):125–32. doi: 10.1093/jnci/djr500.
    1. Wilt TJ, Brawer MK, Barry MJ, Jones KM, Kwon Y, Gingrich JR, et al. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. Contemp Clin Trials. 2009;30(1):81–7. doi: 10.1016/j.cct.2008.08.002.
    1. Hicks C, Koganti T, Giri S, Tekere M, Ramani R, Sitthi-Amom J, et al. Integrative genomic analysis for the discovery of biomarkers in prostate cancer. Biomark Insights. 2014;29(9):39–51. doi: 10.4137/BMI.S13729.
    1. Helfand BT, Catalona WJ, Xu J. A genetic-based approach to personalized prostate cancer screening and treatment. Curr Opin Urol. 2015;25(1):53–8. doi: 10.1097/MOU.0000000000000130.
    1. David S, Chan DW. Biomarkers in prostate cancer: what's new? Curr Opin Oncol. 2014;26(3):259–64. doi: 10.1097/CCO.0000000000000065.
    1. Kader K, Sun J, Reck B, Newcombe PJ, Kim ST, Hsu FC, et al. Potential Impact of Adding Genetic Markers to Clinical Parameters in Predicting Prostate Biopsy Outcomes in Men Following an Initial Negative Biopsy: Findings from the REDUCE Trial. Eur Urol. 2012;62(6):953–61. doi: 10.1016/j.eururo.2012.05.006.
    1. Xu J, Kibel AS, Hu JJ, Turner AR, Pruett K, Zheng SL, et al. Prostate cancer risk associated loci in African Americans. Cancer Epidemiol Biomarkers Prev. 2009;18(7):2145–9. doi: 10.1158/1055-9965.EPI-09-0091.
    1. Freedman ML, Haiman CA, Patterson N, McDonald GJ, Tadon A, Waliszewsk A, et al. Admixture mapping identified 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci U S A. 2006;103(38):14068–73. doi: 10.1073/pnas.0605832103.
    1. Carter HB, Albertson PC, Barry MJ, Etzioni R, Freedland SJ, Greene KL et al. Early Detection of Prostate Cancer: AUA Guidelines. Published 2013. Accessed 04 Mar 2016.
    1. National Comprehensive Cancer Network, Prostate Cancer. National Comprehensive Cancer Network website. Published 2015. Accessed 03 Mar 2016.
    1. Prostate Cancer Prevention and Early Detection. American Cancer society website. . Accessed 03 Mar 2016.
    1. Daskivich TJ. Life Expectancy and Treatment Choice for Men with High-risk Prostate Cancer. Eur Urol. 2015;68(1):59–60. doi: 10.1016/j.eururo.2015.01.006.
    1. Hararah MK, Pollack CE, Garza MA, Yeh HC, Markakis D, Phelan-Emrick DF, et al. The Relationship Between Educational and Prostate-Specific Antigen Testing Among Urban African American Medicare Beneficiaries. J Racial Ethn Health Disparities. 2015;2(2):176–83. doi: 10.1007/s40615-014-0061-z.
    1. Vijayakumar S, Karrison T, Weichselbaum RR, Quadri SF, Awan AM. Racial Differences in Prostate-specific Antigen Levels in Patients with Local-Regional Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 1992;1(7):541–5.
    1. Vijayakumar S, Weichselbaum RR, Vaida F, Dale W, Hellman S. Prostate-Specific Antigen Levels in African Americans Correlate with Insurance Status as an Indicator of Socioeconomic status. Cancer J Sci Am. 1996;2(4):225–33.
    1. Asbell S, Vijayakumar S. Racial Differences in Prostate Specific Antigen Levels in Patients with Local-Regional Prostate Cancer. Prostate. 1997;31(1):42–6. doi: 10.1002/(SICI)1097-0045(19970401)31:1<42::AID-PROS7>;2-K.
    1. Vijayakumar S, Vaida F, Weichselbaum R, Hellman S. Race and the Will Rogers Phenomenon in Prostate Cancer. Cancer J Sci Am. 1998;4(1):27–34.
    1. Abdalla I, Ray P, Vijayakumar S. Race and Serum Prostate-Specific Antigen Levels: Current Status and Future Directions. Semin Urol Oncol. 1998;16(4):207–313.
    1. Saltzman AF, Luo S, Scherrer JF, Carson KD, Grubb RL, III, Hudson MA. Earlier Prostate-specific antigen testing in African American men—Clinical support for the recommendation. Urol Oncol. 2015;33(7):330e9–17. doi: 10.1016/j.urolonc.2015.03.018.
    1. Kryvenko ON, Balise R, Soodana Prakash N, Epstein JI. African American Men with Gleason Score 3 + 3 = 6 Prostate Cancer Produces Less Prostate Specific Antigen than Caucasian Men: A Potential Impact on Active Surveillance. J Urol. 2016;195(2):301–6. doi: 10.1016/j.juro.2015.08.089.
    1. Pietzak EJ, Van Arsdalen K, Patel K, Malkowica SB, Wein AJ, Guzzo TJ. Impact of Race on Selecting Appropriate Patients for Active Surveillance with Seemingly Low-risk Prostate Cancer. Urology. 2015;85(2):436–40. doi: 10.1016/j.urology.2014.09.065.
    1. Kryvenko ON, Carter HB, Trock BJ, Epstein JI. Biopsy Criteria for Determining Appropriateness for Active Surveillance in the Modern Era. Urology. 2014;83(4):869–74. doi: 10.1016/j.urology.2013.12.054.
    1. Sundi D, Kryvenko ON, Carter HB, Ross AE, Epstein JI, Schaeffer EM. Pathological Examination of Radical Prostatectomy Specimens in Men with Very Low Risk Disease at Biopsy Reveals Distinct Zonal Distribution of Cancer in Black American Men. J Urol. 2014;191(1):60–7. doi: 10.1016/j.juro.2013.06.021.
    1. Adams LK, Ferrington LS. New recommendations in prostate cancer screening and treatment. JAAPA. 2014;27(8):14–20.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅